Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Sponsor: TG Therapeutics, Inc.
Summary
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Official title: A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-05-06
Completion Date
2029-01-01
Last Updated
2026-04-07
Healthy Volunteers
No
Conditions
Interventions
Azercabtagene zapreleucel (azer-cel)
IV infusion
Locations (9)
TG Therapeutics Investigational Trial Site
La Jolla, California, United States
TG Therapeutics Investigational Trial Site
Lexington, Kentucky, United States
TG Therapeutics Investigational Trial Site
Ann Arbor, Michigan, United States
TG Therapeutics Investigational Trial Site
Omaha, Nebraska, United States
TG Therapeutics Investigational Trial Site
New York, New York, United States
TG Therapeutics Investigational Trial Site
Rochester, New York, United States
TG Therapeutics Investigational Trial Site
Cleveland, Ohio, United States
TG Therapeutics Investigational Trial Site
Columbus, Ohio, United States
TG Therapeutics Investigational Trial Site
Milwaukee, Wisconsin, United States